Weaning Off Mounjaro: What You Should Know Before Stopping

Does stopping Mounjaro require a gradual taper?

UK prescribing guidance, including the Mounjaro Summary of Product Characteristics published on the eMC, does not specify a compulsory dose-reduction schedule before stopping tirzepatide. This puts it in a different category from some other medicines, like certain antidepressants or steroids, where tapering is formally required to avoid withdrawal effects.

That said, whether you have to wean off Mounjaro and whether you should are slightly different questions. Tirzepatide works by activating GIP and GLP-1 receptors in the gut and brain, slowing gastric emptying and reducing appetite signalling. Once the medicine clears your system, those effects reverse. Stopping from a higher dose means a more abrupt return of normal hunger cues than stepping down gradually would. For some people that difference is manageable; for others it leads to rapid weight regain.

Your prescriber is the right person to weigh that up with you. If you're using tirzepatide through a service like Mounjaro at nume, your clinician reviews your case before every repeat, so planned changes are straightforward to raise. You can also browse our frequently asked questions for broader context on how the treatment programme works.

What happens to appetite and weight after you stop?

This is where the honest answer matters most. The clinical trial evidence is clear that body weight tends to return after tirzepatide is stopped, particularly without sustained lifestyle changes in place. The SURMOUNT-1 trial, published in the New England Journal of Medicine, showed meaningful weight regain in participants who discontinued treatment, a pattern consistent with what has been observed with other GLP-1 receptor agonist medicines.

The mechanism is straightforward. Tirzepatide doesn't change the biological set-point for weight permanently; it modifies appetite signalling while you take it. Once the medicine is gone, hunger returns, often noticeably within a week or two of the last dose. People frequently describe feeling hungry at times that hadn't bothered them during treatment, or finding portion sizes that felt comfortable before starting feel small again.

That's not a failure. Weight is shaped by biology as much as behaviour, and this is a predictable pharmacological outcome, not a personal one. Whether stepping down gradually before stopping softens that transition is worth discussing with your prescriber, particularly if you've been on a higher dose for an extended period. Regular physical activity during treatment helps to preserve lean muscle mass and supports weight maintenance afterwards; our page on Mounjaro and exercise covers that in more detail.

When does stopping become the right clinical decision?

NICE's appraisal of tirzepatide (TA1026) recommends reviewing continuation at six months on the highest tolerated dose. If weight loss at that point is below 5% of starting body weight, the clinical consensus is that continuing is unlikely to deliver sufficient benefit to justify the ongoing cost and treatment burden. Your prescriber makes that assessment based on your actual numbers, not a blanket rule.

Stopping can also be the right decision for planned reasons: surgery, pregnancy planning, a period where supply is disrupted, or simply a personal choice after reaching a stable weight. The NHS England guidance on weight-management injections notes that people planning surgery should tell their anaesthetist and healthcare team that they are taking a GLP-1 or tirzepatide medicine before any procedure.

If you're considering stopping because of side effects rather than a planned decision, that's a different conversation. Most gastrointestinal side effects, particularly nausea and loose stools, are most noticeable at the start of treatment or after a dose increase, and tend to settle within a couple of weeks. Reducing the dose with your prescriber's guidance is often a better route than stopping altogether. Whether you need to wean off tirzepatide before stopping depends on your individual situation, which is precisely what the clinical review process is designed to address.

Thinking about the cost of ongoing treatment is reasonable too. A summary of private market pricing context is available on our Mounjaro cost page, though the clinical question of whether to continue should always come first. If you'd like to talk through your options, speak to our prescribers at no cost through the consultation process.